SML0036
Procarbazine hydrochloride
≥98% (HPLC)
동의어(들):
N-(1-Methylethyl)-4-[(2-methylhydrazinyl)methyl]benzamide hydrochloride
로그인조직 및 계약 가격 보기
크기 선택
모든 사진(1)
크기 선택
보기 변경
About This Item
실험식(Hill 표기법):
C12H19N3O·HCl
CAS Number:
Molecular Weight:
257.76
EC Number:
MDL number:
UNSPSC 코드:
12352200
PubChem Substance ID:
NACRES:
NA.77
추천 제품
분석
≥98% (HPLC)
양식
powder
저장 조건
desiccated
색상
white to tan
solubility
DMSO: ≥18 mg/mL
저장 온도
2-8°C
SMILES string
Cl.CNNCc1ccc(cc1)C(=O)NC(C)C
InChI
1S/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H
InChI key
DERJYEZSLHIUKF-UHFFFAOYSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
애플리케이션
Procarbazine hydrochloride has been used to study its physicochemical property.
Procarbazine, an antineoplastic alkylating agent, may be used to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an anticancer agent. It may be used to study new combination of anticancer drugs.
생화학적/생리학적 작용
Procarbazine hydrochloride is a Antineoplastic alkylating agent
Procarbazine is an antineoplastic alkylating agent widely used in cancer chemotherapy in combination with other compounds. It has multiple mechanisms of action. Procarbazine inhibits protein, RNA and DNA synthesis in addition to being an alkylating agent.
Procarbazine is metabolized to azoprocarbazine either by cytochrome P450 enzyme and monoamine oxidase in an NADPH (nicotinamide adenine diphosphate) dependent or independent manner. It is considered neurotoxic. Procarbazine is used in combination with therapy for treating Hodgkin′s disease.
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 4 Oral - Carc. 1B - Muta. 2 - Repr. 1A
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
Anti-Cancer Drug Design, 143-143 (1994)
Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies.
Michaela Rancea et al.
Journal of the National Cancer Institute, 104(14), NP-NP (2012-07-25)
Mary R Welch et al.
Neuro-oncology, 14(10), 1304-1311 (2012-09-07)
Up to 20% of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens
Lale Erdem-Eraslan et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(3), 328-336 (2012-12-28)
Intrinsic glioma subtypes (IGSs) are molecularly similar tumors that can be identified based on unsupervised gene expression analysis. Here, we have evaluated the clinical relevance of these subtypes within European Organisation for Research and Treatment of Cancer (EORTC) 26951, a
L Kochbati et al.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 16(7), 627-632 (2012-10-23)
To assess the epidemiological, clinical and therapeutic aspects of pediatric Hodgkin disease (HD) and to study prognosis factors. We retrospectively reviewed the medical records of children (≤18 years) with HD treated between 1st January 1994 and 31st December 2004. Chemotherapy
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.